(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 July 2005 (14.07.2005)

PCT

(10) International Publication Number
WO 2005/063762 A1

(51) International Patent Classification[7]: C07D 487/04, A61K 31/5025, A61P 37/02, 25/16 // (C07D 487/04, 249:00, 237:00)

(21) International Application Number:
PCT/US2004/042878

(22) International Filing Date:
17 December 2004 (17.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/531,451	19 December 2003 (19.12.2003)	US
11/016,198	17 December 2004 (17.12.2004)	US

(71) Applicant *(for all designated States except US)*: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GU, Guixue** [US/US]; 8 Greene Dr., Princeton Junction, NJ 08550 (US). **EWING, William, R.** [US/US]; 1193 Waterwheel Dr., Yardley, PA 19067 (US). **MIKKILINENI, Amarendra, B.** [US/US]; 1230 Sycamore Ave., Easton, PA 18040 (US). **PENDRI, Annapurna** [IN/US]; 54 Aspen Dr., Glastonbury, CT 06073 (US). **ELLSWORTH, Bruce, A.** [US/US]; 7 Glenview Dr., Princeton, NJ 08540 (US). **SHER, Philip, M.** [US/US]; 18 Mifflin Ct., Plainsboro, NJ 08536 (US). **GERRITZ, Samuel** [US/US]; 290 N. River St., Guilford, CT 06437 (US). **SUN, Chongqing** [US/US]; 527 Dutch Neck Rd., East Windsor, NJ 08520 (US). **MURUGESAN, Natesan** [US/US]; 42 Millbrook Dr., Princeton Junction, NJ 08550 (US). **WU, Ximao** [US/US]; 54 Cambridge Way, Princeton Junction, NJ 08550 (US).

(74) Agents: **DUNCAN, Sammy, G., Jr.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/063762 A1

(54) Title: AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS



(I)

(57) Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I. including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R^1, R^2, R^3, R^4, R^5, m and n are described herein.